Agenda for October 2026 Cancer Treatments (CTAC) meeting
Source: PHARMAC Information on what the Cancer Treatments Advisory Committee (CTAC) will be considering at its upcoming meeting inOctober 2026. This has been rescheduled from September due to availability. Applications Tislelizumab (branded as TEVIMBRA) for gastric or gastro-oesophageal junction cancer The Committee will discuss an application for tislelizumab for the treatment of people living with…